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Abstract
Spondyloarthritis comprises a group of inflammatory diseases, characterised by inflammation within axial joints and/or
peripheral arthritis, enthesitis and dactylitis. An increasing number of biologic treatments, including biosimilars, are
available for the treatment of spondyloarthritis. Although there are a growing number of randomised controlled trials
assessing treatments in spondyloarthritis, there is a paucity of data from head-to-head studies. Comparative data are
required so that clinicians and payers have the level of evidence required to inform clinical decision-making and health
economic assessments. In the absence of head-to-head studies, statistical methods such as network meta-analyses and
matching-adjusted indirect comparisons (MAICs) are used for assessing comparative effectiveness.
Network meta-analysis can be used to compare treatments for trials using a common comparator (e.g. placebo);
however, for those without a common comparator or where considerable heterogeneity exists between the study
populations, a MAIC that controls for differences in study design and baseline patient characteristics may be used.
MAICs, unlike network meta-analyses, are of value for longer-term comparisons beyond the placebo-controlled phase
of clinical trials, which is important for chronic diseases requiring long-term treatment, like spondyloarthritis. At present,
there are a number of limitations that restrict the effectiveness of MAIC, such as the poor availability of individual
patient-level data from trials, which results in patient-level data from one trial being compared with published whole-
population data from another. Despite these limitations, drug reimbursement agencies are increasingly accepting MAIC
as a means of comparative effectiveness and greater methodological guidance is needed.
This report highlights a number of challenges that are specific to conducting comparative studies like MAIC in
spondyloarthritis, including disease heterogeneity, the paucity of biomarkers and the duration of studies required for
radiographic endpoints in this slow-progressing disease.
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Background
Spondyloarthritis (SpA) represents a group of inflammatory
arthritides, mainly axial SpA and psoriatic arthritis (PsA),
which share common genetic features and a chronic
clinical course. There are a growing array of biologic agents
and biosimilar medications, targeting key mediators
involved in the inflammatory process, available to rheuma-
tologists. Although there are an increasing number of
randomised controlled trials (RCTs) assessing treatments
in SpA, there is a paucity of data from head-to-head stud-
ies, so other forms of treatment comparison are needed.
This commentary summarises the key findings of an indus-
try-sponsored roundtable discussion involving eight expert
rheumatologists and two medical personnel from the
pharmaceutical industry, that was conducted in April 2017
to obtain advice and perspectives on comparative studies in
SpA.
Network meta-analyses and MAICs
Indirect comparisons can infer the relative effectiveness of
different treatments. For trials using common comparators
(e.g. Drug A vs Drug B and Drug B vs Drug C), treatments
can be indirectly compared using a network meta-analysis
[1]. Where there is no common comparator to facilitate a
network meta-analysis, or where considerable heterogeneity
exists between the study populations, a matching-adjusted
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indirect comparison (MAIC) that controls for differences
in study design and baseline patient characteristics may be
used [1, 2]. Significant debate exists regarding which indir-
ect comparison method is optimal (Table 1) [3, 4].
Several MAICs have been published comparing biologics
for the treatment of AS [5–12] and PsA [13–24], although
only two as full-length papers [13, 25]; these analyses com-
pare patient-level data from a trial of a given treatment (i.e.
index trial) with published data for another treatment
(Table 2) [1]. Until the National Institute of Health and
Care Excellence (NICE) published technical guidance on
this topic in December 2016 [2], the lack of quality criteria
made it challenging to interpret the results of MAICs; how-
ever, further methodological guidance would be of value.
Key points to consider for MAICs
First, making individual patient-level data available
from trials will facilitate MAIC and circumvent the
need to compare patient-level data from one trial
with published whole-population data from another.
Second, selection of baseline parameters for matching
is critical. Ideally, these should be based on estab-
lished key parameters that are known, from published
data and expert opinion, to influence outcomes.
Third, when placebo response is available, this can
inform quality of matching. Additionally, anchored
comparisons (i.e. having a common comparator) are
preferred to unanchored analysis [26]. Fourth, if the
number of patients included after matching is small,
caution is needed when inferring results. Fifth,
sensitivity analyses should be conducted, varying the
matching parameters to assess the robustness of
results or cross-validating the results using data from
other trials. Lastly, a thorough and detailed descrip-
tion of the methodology is essential when reporting
results.
Challenges for MAICs in spondyloarthritis
In comparison to rheumatoid arthritis, SpA has a het-
erogeneous clinical presentation characterised by inflam-
mation affecting the axial skeleton (the spine and
sacroiliac joints), peripheral joints and entheses and
extra-articular sites, such as the eye (uveitis), skin (psor-
iasis) and gut (inflammatory bowel disease [IBD]) [27].
This heterogeneity adds complexity when defining the
inclusion criteria for a clinical study population and also
for any subsequent MAIC that might only include a sub-
set of the index population in order to match the com-
parator population. Treatment history is also important,
as many newer studies include patients who have failed
previous biologics. Information about the inclusion/ex-
clusion criteria, recruitment processes and baseline char-
acteristics of study populations are thus needed to
inform indirect comparisons.
The complex and heterogeneous nature of SpA con-
founds the identification of a single representative out-
come measure [28]. Although composite scores have
been developed to assess disease activity in rheumatoid
arthritis, the identification of a common composite
measure for SpA conditions, including PsA, has proved
more challenging due to the involvement of multiple
organ systems and the variety of clinical presentations
[28]. For axial SpA, including AS, the Ankylosing Spon-
dylitis Disease Activity Score (ASDAS) is increasingly
used, while in PsA, the use of different measures, such
as the Composite Psoriatic Arthritis Disease Activity
Index (CPDAI), the Psoriatic Arthritis Disease Activity
Score (PASDAS), Minimal Disease Activity (MDA) and
the Disease Activity Index for Psoriatic Arthritis
(DAPSA), illustrates that no consensus has yet been
reached. As there are limited data available for more re-
cently developed outcomes (e.g. ASDAS), this restricts
the utility of this outcome in MAICs. In addition, the
heterogeneity of the individual disease manifestations
Table 1 Advantages/disadvantages of NMA and MAIC
Network meta-analysis (NMA) Matching-adjusted indirect comparison (MAIC)
Advantages
• Compares multiple treatments using published aggregate data
• Can connect head-to-head RCTs and other RCTs via a common
comparator (usually placebo)
• Multiple simultaneous indirect paths
• Based on relative effects, so randomisation is preserved
• Established methodology
• Reduces heterogeneity between trials by matching the patient population
• Treatment effects have clear clinical context for interpretation
• Possible with and without placebo adjustment
• Long-term analyses feasible
Disadvantages
• Assumes trials are comparable in terms of design and population
(low heterogeneity)
• Requires a common comparator (connected evidence network)
• Often only short-term comparison due to lack of a long-term
connected network (placebo switching)
• Evolving method—NICE Technical Support Document published in
December 2016 [2]
• Interferes with/breaks randomisation
• Reduced patient sample size
• Only a single indirect path
• Can only match observed characteristics, so heterogeneity may remain
Adapted from Ishak et al. [1]
MAIC matching-adjusted indirect comparison, NMA network meta-analysis, RCT randomised controlled trials
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included in composite scores may limit which score is
compared in MAICs. For example, in ASDAS,
C-reactive protein or erythrocyte sedimentation rate
values are included, both of which may be affected by
biologic disease-modifying antirheumatic drugs
(DMARDs); however, neither of these are included in
the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI). Since not every patient with axial SpA will
show a positive inflammatory finding in their laboratory
examination or even fluctuation of these parameters,
treatment with biologic DMARDs may affect ASDAS
scores more in patients with inflammation than in those
without [29]. Thus, certain composite scores may be
more difficult to weigh the individual populations based
on the heterogeneity of the individual disease
manifestations.
Patient-reported outcomes (PROs) are important for
consideration in health economic models for SpA owing to
the considerable impact of PsA and AS on health-related
quality of life. A recent systematic review identified 60
unique PRO measures for SpA, which differed in their de-
gree of correlation with clinical variables [30]. The same
study identified a lack of validation of PROs for use across
SpA subtypes. For individual SpA subtypes, PROs used in-
clude the BASDAI and the Bath Ankylosing Spondylitis
Functional Index (BASFI) in AS, while the Psoriatic
Table 2 Overview of published MAIC in SpA*
Year Patient-level data Published data Sponsor Type of publication
Treatment A (trial name; ClinicalTrials.gov identifier) Treatment B (trial name; ClinicalTrials.gov identifier)
Ankylosing spondylitis
2016 Secukinumab (MEASURE 2; NCT01649375) Adalimumab (ATLAS; NCT00195819) Novartis Abstract [5]
2016 Adalimumab (ATLAS; NCT00195819) Secukinumab (pooled MEASURE 1
[NCT01358175], MEASURE 2 [NCT01649375])
Abbvie Abstract [6]
2016 Secukinumab (MEASURE 2; NCT01649375) Adalimumab (ATLAS; NCT00195819) Novartis Abstract [7]
2016 Secukinumab (MEASURE 1; NCT01358175) Adalimumab (ATLAS; NCT00195819) Novartis Abstract [8]
2016 Secukinumab (pooled MEASURE 1 [NCT01358175],
MEASURE 2 [NCT01649375])
Adalimumab (ATLAS; NCT00195819) Novartis Abstract [9]
2017 Secukinumab (pooled FUTURE 1 [NCT01392326],
FUTURE 2 [NCT01752634])
Golimumab (GO-RAISE; NCT00265083) Novartis Abstract [10]
2017 Secukinumab (pooled FUTURE 1 [NCT01392326],
FUTURE 2 [NCT01752634])
Golimumab (GO-RAISE; NCT00265083) Novartis Abstract [11]
2017a Secukinumab (MEASURE 2; NCT01649375) Adalimumab (ATLAS; NCT00195819) Novartis Abstract [12]
Psoriatic arthritis
2013 Adalimumab (ADEPT; NCT00195689) Etanercept (Mease et al. 2004), infliximab
(IMPACT 2; NCT00051623)
Abbvie Manuscript [13]
2015 Adalimumab (ADEPT; NCT00195689) Secukinumab (pooled FUTURE 1
[NCT01392326], FUTURE 2 [NCT01752634])
Abbvie Abstract [14]
2016 Secukinumab (FUTURE 2; NCT01752634) Adalimumab (ADEPT; NCT00195689) Novartis Abstract [15]
2016 Secukinumab (FUTURE 2; NCT01752634) Adalimumab (ADEPT; NCT00195689) Novartis Abstract [16]
2016 Secukinumab (FUTURE 2; NCT01752634) Etanercept (Mease et al. 2004) Novartis Abstract [17]
2016 Secukinumab (pooled FUTURE 1 [NCT01392326],
FUTURE 2 [NCT01752634])
Adalimumab (ADEPT; NCT00195689) Novartis Abstract [18]
2016 Secukinumab (FUTURE 2; NCT01752634) Infliximab (IMPACT 2; NCT00051623) Novartis Abstract [19]
2016a Secukinumab (FUTURE 2; NCT01752634) Adalimumab (ADEPT; NCT00195689) Novartis Abstract [20]
2017 Secukinumab (pooled FUTURE 1 [NCT01392326],
FUTURE 2 [NCT01752634])
Interferon (IMPACT 2; NCT00051623) Novartis Abstract [21]
2017a Secukinumab (FUTURE 2; NCT01752634) Infliximab (IMPACT 2; NCT00051623) Novartis Abstract [22]
2017a Secukinumab (FUTURE 2; NCT01752634) Etanercept (Mease et al. 2004) Novartis Abstract [23]
2017a Secukinumab (FUTURE 2; NCT01752634) Adalimumab (ADEPT; NCT00195689) Novartis Abstract [24]
2017 Adalimumab (ADEPT; NCT00195689) Secukinumab (pooled FUTURE 1
[NCT01392326], FUTURE 2 [NCT01752634])
Abbvie Manuscript [25]
*Up to December 2017
aCost per responder analysis
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Arthritis Quality of Life (PsAQoL) and Health Assessment
Questionnaire Disability Index (HAQ-DI) are used in PsA.
Little data is available on the use of these PROs in MAICs.
In the two published MAICs in PsA, no statistically signifi-
cant differences were observed between treatment arms in
measurements of HAQ-DI, although differences in efficacy
were noted in other more stringent endpoints, such as
ACR and PASI response rates [13, 25]. Further research is
needed on the effectiveness of comparing treatment effects
on PROs using MAICs.
Another key challenge in SpA is the lack of reliable bio-
markers of disease activity, structural damage and new
bone formation [27]. Proxy outcomes representative of
the underlying disease process, discomfort and/or disabil-
ity are, therefore, frequently used in rheumatology clinical
studies (e.g. disease activity outcome measures, such as
the American College of Rheumatology (ACR) 20, are
used as primary outcomes to discriminate the efficacy of
newer drugs from placebo in RCTs, despite the fact that
these parameters are not used clinically) [27, 28].
Endpoints for MAICs in spondyloarthritis
Clinically meaningful hard endpoints are needed to demon-
strate the additional value (e.g. improved disease status,
long-term safety or reduced radiographic progression) of
treatments for comparisons on the relative effectiveness to
be made. Progression of joint damage is considered irrevers-
ible in SpA, and its prevention is an important treatment
goal; this outcome can be assessed using imaging and a vali-
dated proxy scoring system, such as the modified Stoke An-
kylosing Spondylitis Spinal Score (mSASSS) in AS and axial
SpA [31], and by various scores of radiographic damage in
hands and forefeet (e.g. the Sharp van der Heijde [SHS]
method) in PsA [32]. While the mSASSS and the SHS are
currently the most used measures of structural damage [33,
34], magnetic resonance imaging (MRI) has been proposed
as a potentially more sensitive alternative [35]. Achieving re-
mission, or low disease activity, which is the ultimate goal of
SpA treatment [27], is also an example of clinically meaning-
ful hard endpoints for head-to-head studies.
In contrast to the relatively rapid progression reported
in rheumatoid arthritis [36], structural changes in axial
SpA/AS generally take several years to progress. The
shortest follow-up time in AS, based on the reliability and
sensitivity to change of the mSASSS, is 2 years [37], while
radiographic damage in PsA can be detected within 2
years of disease onset in almost half of patients [38]. The
duration required to assess radiographic endpoints is,
therefore, an important consideration when conducting
comparative studies in SpA.
Considerations for future head-to-head studies
Sample size estimations take into account the study de-
sign (superiority, equivalence, non-inferiority) and the
study outcomes. Since more domains (axial and periph-
eral involvement, arthritis, enthesitis, dactylitis, psoriasis,
uveitis, IBD etc.) have to be considered in SpA assess-
ments, the identification of primary and secondary end-
points and sample size estimations are key issues when
planning head-to-head studies. Whole-body MRI is a
promising new technique for future clinical trials, as it
allows assessment of both peripheral and axial joints
and entheses [39].
Aside from traditional head-to-head studies, of which
there are few published in SpA, a number of other com-
parative study designs exist, including trials comparing
strategies instead of individual drugs and trials with an ac-
tive control treatment arm. The TIght COntrol of Psori-
atic Arthritis (TICOPA) trial—the first and only pragmatic
RCT in PsA—compared intensive management versus
standard care in early PsA [40]. The recently published
SPIRIT P1 trial in PsA is an example of a placebo- and
active-controlled clinical trial that compared two regimens
of ixekizumab and an active adalimumab reference arm to
treatment with placebo (note: the study was not powered
to directly compare adalimumab and ixekizumab) [41].
Conclusions
Indirect comparisons may be used to infer the relative ef-
fectiveness of different treatments in the absence of
head-to-head data and can supplement the evidence from
traditional sources. MAICs provide an important technique
to control for differences in study design and population
[13]; however, the greater the imbalance in the study design
and/or population characteristics, the lower the actual
sample size/precision of the analysis. Allowing academic
researchers access to anonymised patient-level data from
clinical trials may help improve the quality of MAICs as full
data sets from each study could be compared. MAICs, un-
like network meta-analyses, are of value for longer-term
comparisons beyond the placebo-controlled phase of
clinical trials; this is an important consideration for chronic
diseases like AS and PsA whose management focuses on
long-term treatment goals. Care should be taken when
choosing endpoints to compare in longer-term extension
arms, as some can be influenced by issues of unblinding
and expectation bias owing to the lack of a concurrent pla-
cebo arm. Although MAICs have a number of limitations,
including the exploratory nature of the analysis, they may
be of particular value in generating hypotheses to inform
the design of head-to-head studies. Despite these limita-
tions, drug reimbursement agencies, such as the Australian
Pharmaceutical Benefits Advisory Committee (PBAC), the
UK NICE, the Scottish Medicines Consortium (SMC) and
the Canadian Agency for Drug and Technologies in Health
(CADTH), are increasingly accepting MAIC as a means of
comparative effectiveness [42]. Improvements in the selec-
tion of clinical study endpoints and the general reporting of
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clinical trial data in SpA could greatly improve the quality
of data to allow more informative indirect comparisons
between the myriad of emerging therapies for SpA.
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